Multiple Sclerosis: Unprecedented Progress But Significant Challenges Ahead.
作者信息
Conway Devon S, Hua Le H, Cohen Jeffrey A
机构信息
Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH, 44195, USA.
Lou Ruvo Center for Brain Health, Cleveland Clinic Foundation, Las Vegas, NV, 89106, USA.
出版信息
Neurotherapeutics. 2017 Oct;14(4):832-834. doi: 10.1007/s13311-017-0576-1.
Abstract
摘要
相似文献
1
Multiple Sclerosis: Unprecedented Progress But Significant Challenges Ahead.多发性硬化症：取得前所未有的进展，但前路仍有重大挑战。
Neurotherapeutics. 2017 Oct;14(4):832-834. doi: 10.1007/s13311-017-0576-1.
2
[Pathogenetic treatment of multiple sclerosis: the present and the future].[多发性硬化症的发病机制治疗：现状与未来]
Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(7 Suppl 2):90-9.
3
Can we quantify the benefits of DMDs in multiple sclerosis?
Lancet Neurol. 2006 Apr;5(4):290-1. doi: 10.1016/S1474-4422(06)70389-1.
4
Altering the course of disease in multiple sclerosis: many large steps forward.改变多发性硬化症的疾病进程：向前迈进了许多大步。
Arq Neuropsiquiatr. 2015 Sep;73(9):731-2. doi: 10.1590/0004-282X20150123.
5
Breastfeeding in the Multiple Sclerosis Patient.
Breastfeed Med. 2019 Jul/Aug;14(6):356-358. doi: 10.1089/bfm.2019.0120. Epub 2019 Jun 17.
6
Decreasing longitudinal use of glucocorticosteroids in multiple sclerosis.在多发性硬化症中减少糖皮质激素的长期使用。
Mult Scler Relat Disord. 2018 Oct;25:173-174. doi: 10.1016/j.msard.2018.07.040. Epub 2018 Jul 24.
7
The new therapeutic landscape in multiple sclerosis: exciting times and new perspectives.
Curr Opin Neurol. 2014 Jun;27(3):243-5. doi: 10.1097/WCO.0000000000000101.
8
[Teriflunomide (Aubagio). New treatment for multiple sclerosis].[特立氟胺（奥巴捷）。多发性硬化症的新疗法]
Perspect Infirm. 2014 May-Jun;11(3):56.
9
[Clinical recommendations of the Russian Neurological Society for the treatment of typical cases of multiple sclerosis with disease modifying drugs].
Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(7 Suppl 2):154.
10
Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis - No.利妥昔单抗是治疗多发性硬化症的一种可接受的奥瑞珠单抗替代药物——否。
Mult Scler. 2018 Aug;24(9):1159-1161. doi: 10.1177/1352458518757931. Epub 2018 Feb 22.
本文引用的文献
1
Cladribine to Treat Relapsing Forms of Multiple Sclerosis.克拉屈滨治疗多发性硬化的复发性形式。
Neurotherapeutics. 2017 Oct;14(4):874-887. doi: 10.1007/s13311-017-0573-4.
2
Remyelinating Pharmacotherapies in Multiple Sclerosis.多发性硬化症中的髓鞘修复治疗药物。
Neurotherapeutics. 2017 Oct;14(4):894-904. doi: 10.1007/s13311-017-0577-0.
3
Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials.患者报告结局的演变及其在多发性硬化症临床试验中的作用。
Neurotherapeutics. 2017 Oct;14(4):934-944. doi: 10.1007/s13311-017-0571-6.
4
Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.与多发性硬化症治疗相关的进行性多灶性白质脑病的诊断与治疗。
Neurotherapeutics. 2017 Oct;14(4):961-973. doi: 10.1007/s13311-017-0570-7.
5
Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis.引入 HEET：儿科发病多发性硬化症的高效早期治疗的论据。
Neurotherapeutics. 2017 Oct;14(4):985-998. doi: 10.1007/s13311-017-0568-1.
6
Five Questions Answered: A Review of Autologous Hematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis.五个问题解答：自体造血干细胞移植治疗多发性硬化症的综述。
Neurotherapeutics. 2017 Oct;14(4):888-893. doi: 10.1007/s13311-017-0564-5.
7
Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA.美国多发性硬化症治疗的经济学和成本效益分析。
Neurotherapeutics. 2017 Oct;14(4):1018-1026. doi: 10.1007/s13311-017-0566-3.
8
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.鞘氨醇 1-磷酸受体调节剂治疗多发性硬化。
Neurotherapeutics. 2017 Oct;14(4):859-873. doi: 10.1007/s13311-017-0565-4.
9
Wellness and the Role of Comorbidities in Multiple Sclerosis.健康与多发性硬化症共病的作用。
Neurotherapeutics. 2017 Oct;14(4):999-1017. doi: 10.1007/s13311-017-0563-6.
10
Ethical Considerations of Patient-Funded Research for Multiple Sclerosis Therapeutics.患者资助多发性硬化症治疗研究的伦理考虑
Neurotherapeutics. 2017 Oct;14(4):945-951. doi: 10.1007/s13311-017-0560-9.
Zotero 插件